对《氟喹诺酮及氟喹诺酮/皮质类固醇联合治疗肌腱断裂的相对和绝对风险：基于人群的巢式病例对照研究》的更正

Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.

作者信息

Morales Daniel R, Slattery Jim, Pacurariu Alexandra, Pinheiro Luis, McGettigan Patricia, Kurz Xavier

机构信息

Division of Population Health and Genomics, School of Medicine, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, UK.

Pharmacovigilance and Epidemiology Department, European Medicines Agency, London, UK.

出版信息

Clin Drug Investig. 2019 Feb;39(2):215. doi: 10.1007/s40261-019-00755-y.

DOI:10.1007/s40261-019-00755-y

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6394636/

Abstract

The article Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study, written by Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X, was originally published Online First without open access.

摘要

文章《氟喹诺酮及氟喹诺酮/皮质类固醇联合治疗导致肌腱断裂的相对和绝对风险：基于人群的巢式病例对照研究》，作者为莫拉莱斯·DR、斯莱特里·J、帕库里乌·A、皮涅罗·L、麦吉蒂根·P、库尔兹·X，最初以在线优先发表形式发布，无开放获取权限。

相似文献

1

Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.对《氟喹诺酮及氟喹诺酮/皮质类固醇联合治疗肌腱断裂的相对和绝对风险：基于人群的巢式病例对照研究》的更正

Clin Drug Investig. 2019 Feb;39(2):215. doi: 10.1007/s40261-019-00755-y.

2

Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.氟喹诺酮类药物与氟喹诺酮类/皮质类固醇联合治疗肌腱断裂的相对和绝对风险：基于人群的巢式病例对照研究。

Clin Drug Investig. 2019 Feb;39(2):205-213. doi: 10.1007/s40261-018-0729-y.

3

Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.《氟喹诺酮及氟喹诺酮/皮质类固醇联合治疗导致肌腱断裂的相对及绝对风险：基于人群的巢式病例对照研究》补遗

Clin Drug Investig. 2019 Jun;39(6):591-594. doi: 10.1007/s40261-019-00792-7.

4

Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.跟腱断裂及其与氟喹诺酮类抗生素和管理式医疗人群中其他潜在风险因素的关联。

Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):784-92. doi: 10.1002/pds.1214.

5

Fluoroquinolone use and the change in incidence of tendon ruptures in the Netherlands.荷兰氟喹诺酮类药物的使用情况与肌腱断裂发病率的变化

Pharm World Sci. 2001 Jun;23(3):89-92. doi: 10.1023/a:1011254030271.

6

Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study.氟喹诺酮类药物的使用与跟腱断裂风险：一项基于人群的队列研究。

Eur J Clin Pharmacol. 2007 May;63(5):499-503. doi: 10.1007/s00228-007-0265-9. Epub 2007 Mar 3.

7

Pathogenesis of tendon rupture secondary to fluoroquinolone therapy.氟喹诺酮类药物治疗继发肌腱断裂的发病机制。

Orthop Nurs. 2007 May-Jun;26(3):175-82; quiz 183-4. doi: 10.1097/01.NOR.0000276969.09808.2c.

8

Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study.氟喹诺酮治疗引发肌腱炎的证据：一项病例对照研究。

Drug Saf. 2006;29(10):889-96. doi: 10.2165/00002018-200629100-00006.

9

Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?氟喹诺酮类药物相关性肌腱病：左氧氟沙星的风险最大吗？

Pharmacotherapy. 2016 Jun;36(6):679-93. doi: 10.1002/phar.1761. Epub 2016 Jun 11.

10

Fluoroquinolone-associated bilateral patellar tendon rupture: a case report and review of the literature.氟喹诺酮类药物相关的双侧髌腱断裂：一例病例报告及文献复习

Mil Med. 2010 Jun;175(6):457-9. doi: 10.7205/milmed-d-09-00142.

引用本文的文献

1

Abandon Informed Consent in Favor of Probability-Based, Shared Decision-Making Following the Wishes of a Reasonable Person.放弃知情同意，转而支持基于概率的、遵循理性人意愿的共同决策。

J Patient Exp. 2022 Jun 7;9:23743735221106599. doi: 10.1177/23743735221106599. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。